Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanide SCHEMBL28115703 | 0.72 | ALDH1A1 (0.53) | RAPGEF4ALDH1A1TSHRCYP1A2CYP2A6 | |
| Cyanide SCHEMBL30050757 | 0.72 | ALDH1A1 (0.53) | RAPGEF4ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL4455588 | 0.71 | RAPGEF4 (0.45) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL28951 | 0.69 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL317299 | 0.69 | RAPGEF4 (0.50) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1551822 | 0.69 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| Ethyne SCHEMBL28084460 | 0.68 | ALDH1A1 (0.57) | RAPGEF4ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL13673473 | 0.67 | RAPGEF4 (0.41) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL5180888 | 0.67 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL10412763 | 0.67 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848369-B | Eribulin intermediate and synthesis method and application thereof | 北京天一绿甫医药科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20220204523-A1 | INTERMEDIATE OF ERIBULIN AND SYNTHESIS METHOD AND USE THEREOF | BEIJING TIENYI LUFU PHARMATECH CO. LTD. (CN) | 2022-06-30 | — | — | US | claimed |
| EP-3925948-A1 | INTERMEDIATE OF ERIBULIN, SYNTHESIS METHOD THEREFOR AND USE THEREOF | Beijing Tienyi Lufu Pharmatech Co. Ltd. (CN) | 2021-12-22 | — | — | EP | claimed |
| CN-111848369-A | Eribulin intermediate, and synthesis method and application thereof | 北京天一绿甫医药科技有限公司 | 2020-10-30 | — | — | CN | claimed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | claimed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | claimed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | claimed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | claimed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | claimed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | claimed |
| US-8211859-B2 | α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-03 | — | — | US | claimed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | claimed |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2011-02-03 | — | — | US | claimed |
| WO-2008047249-A9 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-23 | — | — | WO | claimed |
| EP-2099813-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Centre National de la Recherche Scientifique (FR) | 2009-09-16 | — | — | EP | claimed |
| WO-2008047174-A1 | ALPHA-GALACTOSYLCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-24 | — | — | WO | claimed |
| WO-2008047249-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-24 | — | — | WO | claimed |
| US-11976081-B2 | Intermediate of eribulin and synthesis method and use thereof | BEIJING TIENYI LUFU PHARMATECH CO. LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976081-B2 | Intermediate of eribulin and synthesis method and use thereof | ERLIN1, ERLIN2, XPO5 | RAPGEF4 2826/4885ALDH1A1 3584/4885KDM4E 4044/4885 |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GALE, GALNT14, GALC | RAPGEF4 3204/4885ALDH1A1 935/4885KDM4E 2458/4885 |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RAPGEF4 527/4885ALDH1A1 1005/4885KDM4E 3559/4885 |
| US-20220204523-A1 | INTERMEDIATE OF ERIBULIN AND SYNTHESIS METHOD AND USE THEREOF | ERLIN1, ERLIN2, XPO5 | RAPGEF4 2826/4885ALDH1A1 3584/4885KDM4E 4044/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RAPGEF4 527/4885ALDH1A1 1005/4885KDM4E 3559/4885 |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RAPGEF4 527/4885ALDH1A1 1005/4885KDM4E 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.